secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0001193125-23-251917
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology prices $55M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Priced public offering of 7,370,690 shares at $6.38/share and pre-funded warrants for 1,250,000 shares at $6.379/warrant.
- Gross proceeds expected ~$55M before underwriting discounts; offering to close Oct 10, 2023.
- Net proceeds to fund evorpacept clinical development including ASPEN-06 trial, working capital.
- Underwriters granted 30-day option to purchase up to 1,293,103 additional shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312523251917/0001193125-23-251917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312523251917/d534693d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-251917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer